Should I buy Baxter International (BAX) stock or is it too late?

Baxter International · Health Care · price $26
Logo Baxter InternationalSee the full Baxter International (BAX) profile
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Stifel68% of its targets hit on this sector (299 calls tested). It aims for $28 (+8.0 %), call made on August 1, 2026, maturing on August 1, 2027 (27 d ago).

The 6 reliable analysts $26.50+2.2 %
The 2 other firms $25.50-1.7 %
How to read it: the 6 reliable firms are not filtered by optimism — 3 aim above the price, 3 below, hence their $26.50 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Baxter International

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.
Firm% rightGain vs sectorCallsAims for
Goldman Sachs88 %+19.6 %8$21 -19%
UBS83 %+11.2 %6$25 -4%
Wells Fargo62 %+3.2 %8$23 -11%
JP Morgan43 %-2.0 %7$36 +39%
B of A Securities60 %-2.3 %5$45 +74%
Evercore ISI Group33 %-2.7 %6$24 -7%
Barclays45 %-4.8 %20$27 +4%
Morgan Stanley44 %-8.9 %18$15 -42%
In short — Should you invest in Baxter International? Is it too late, still worth it? Analysts are split (25% buy, median target $26, i.e. +0%). We give you both sides, with the numbers — not advice.

✅ Reasons to believe

  • Few solid positives from analysts right now: of 8 ratings, only 2 buys, and the median price target ($26) is barely above the price (+0%, at $26). Caution prevails.

⚠️ Reasons to hesitate

  • Even the most reliable firm on BAX, Goldman Sachs (88% hit rate, 8 scored calls), only targets $21 (call made on July 15, 2026, maturing on July 15, 2027) (-19%) in its most recent call, and $22 (call made on October 31, 2025, maturing on October 31, 2026) (-15%) in the one coming due soonest. The stock may already have run past its target.
  • The consensus is not unanimous: of 8 ratings, 6 are neutral.
  • Limited upside: the median target is only +0% from the current price.
  • A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on BAX

Median target $26 (+0%) · 8 ratings · Hold consensus

Strong Buy00%
Buy225%
Hold675%
Sell00%
Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Baxter International now?

We won't decide for you. The facts: 25% of analysts rate it a buy, median target $26 (+0%), and Goldman Sachs (most reliable on BAX, 88%) targets $21. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Baxter International?

The stated upside is small: the median target ($26) sits just +0% from the price ($26) (most reliable on BAX: Goldman Sachs, 88%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Baxter International still worth investing in?

It depends on the gap between the price ($26) and its estimated value: analysts target $26 on median (+0%), with 25% buys (most reliable on BAX: Goldman Sachs, 88%). Cross-check with their real reliability on BAX and the cautions above. Information, not advice.

What's the main risk in buying BAX?

Even the most reliable firm on BAX, Goldman Sachs (88% hit rate, 8 scored calls), only targets $21 (call made on July 15, 2026, maturing on July 15, 2027) (-19%) in its most recent call, and $22 (call made on October 31, 2025, maturing on October 31, 2026) (-15%) in the one coming due soonest. The stock may already have run past its target.

→ Go deeper: the full Baxter International profile (consensus, analyst reliability, price target, performance).

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)